BioMarin Pharmaceutical Q2 revenue rises 4%

The "Follow This Story" feature will notify you when any articles related to this story are posted.

When you follow a story, the next time a related article is published — it could be days, weeks or months — you'll receive an email informing you of the update.

If you no longer want to follow a story, click the "Unfollow" link on that story. There's also an "Unfollow" link in every email notification we send you.

This tool is available only to subscribers; please make sure you're logged in if you want to follow a story.

Please note: This feature is available only to subscribers; make sure you're logged in if you want to follow a story.


SAN RAFAEL — BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported a loss of $37.4 million in its second quarter, more than double the midyear loss a year before.

The San Rafael, California-based company said it had a loss of 21 cents per share. Earnings, adjusted for one-time gains and costs, were 9 cents per share.

The results did not meet Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 17 cents per share.

The rare disease biopharmaceutical posted revenue of $387.8 million in the period, also falling short of Street forecasts and down 4.0% over 12 months. Nine analysts surveyed by Zacks expected $410.9 million.

BioMarin expects full-year revenue in the range of $1.68 billion to $1.75 billion.

BioMarin shares have decreased nearly 5% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $81, a drop of 20% in the last 12 months.

Show Comment

Our Network

Santa Rosa Press Democrat
Sonoma Index-Tribune
Petaluma Argus Courier
Sonoma Magazine
Bite Club Eats
La Prensa Sonoma
Emerald Report
Spirited Magazine